Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 350.00K | 342.00K | 654.00K | 473.00K | 723.00K | 206.00K |
Gross Profit | 276.00K | 272.00K | 533.00K | 447.00K | 434.00K | 141.00K |
EBITDA | -28.35M | -33.69M | -43.24M | -25.21M | -8.22M | -16.92M |
Net Income | -29.07M | -39.40M | -49.50M | -15.28M | -9.74M | -19.28M |
Balance Sheet | ||||||
Total Assets | 25.31M | 27.34M | 52.34M | 44.49M | 63.06M | 68.24M |
Cash, Cash Equivalents and Short-Term Investments | 9.83M | 12.15M | 35.00M | 23.32M | 50.29M | 59.27M |
Total Debt | 20.94M | 20.84M | 32.16M | 31.82M | 24.04M | 4.32M |
Total Liabilities | 30.29M | 36.19M | 38.95M | 41.26M | 50.47M | 67.90M |
Stockholders Equity | -4.97M | -8.86M | 13.39M | 3.24M | 12.60M | 341.00K |
Cash Flow | ||||||
Free Cash Flow | -19.26M | -21.34M | -30.50M | -44.19M | -35.96M | -19.32M |
Operating Cash Flow | -19.25M | -21.33M | -30.17M | -39.01M | -34.62M | -18.93M |
Investing Cash Flow | 6.25M | 6.32M | -1.50M | -10.16M | -1.33M | -387.00K |
Financing Cash Flow | 1.16M | -1.53M | 42.16M | 17.25M | 27.11M | 69.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $23.85M | ― | -93.19% | ― | 6.96% | 32.32% | |
52 Neutral | $35.48M | ― | -1738.36% | ― | -43.55% | 69.81% | |
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
45 Neutral | $65.14M | ― | 256.43% | ― | 238.96% | 35.96% | |
42 Neutral | $22.65M | ― | -70.06% | ― | 146.47% | 57.85% | |
41 Neutral | $35.67M | ― | -853.05% | ― | ― | 34.97% | |
39 Underperform | $20.14M | ― | -1094.50% | ― | 11.40% | -18.18% |
On April 28, 2025, Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to offer and sell shares of its common stock, aiming to raise up to $25 million. By July 3, 2025, Clene had filed a prospectus supplement for an additional $2,015,000 in shares, indicating ongoing efforts to secure funding for its operations and potentially strengthen its market position.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
On June 30, 2025, Clene Inc. announced a regulatory update following a constructive Type C meeting with the FDA regarding its neurofilament biomarker analysis plan. The FDA provided supportive feedback on Clene’s proposed statistical analysis plan for its NIH-sponsored Expanded Access Program, which supports ALS patients treated with CNM-Au8®. The company plans to conduct neurofilament light (NfL) biomarker analyses early in the fourth quarter of 2025 and aims to submit a new drug application for ALS under the accelerated approval pathway by the end of 2025. Additionally, Clene confirmed two more FDA meetings in the third quarter of 2025 to discuss ALS survival data and the MS clinical development program, which could further advance its ALS and MS therapeutic initiatives.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
On June 17, 2025, Clene Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(2), as its market value of listed securities has been $35.0 million or greater for 10 consecutive business days from June 2 to June 16, 2025. This compliance ensures Clene’s continued listing on Nasdaq, closing the matter and potentially stabilizing its market position.
The most recent analyst rating on (CLNN) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
On May 22, 2025, Clene Inc. held its Annual Meeting of Stockholders, where the stockholders approved an amendment to the company’s 2020 Stock Plan, increasing the number of shares of common stock reserved for issuance by 800,000 shares. Additionally, the Board of Directors approved an amendment to the compensation program for nonemployee directors, adjusting stock option grants to reflect a reverse stock split from July 2024. These changes are expected to impact the company’s stock management and director compensation structure, potentially affecting shareholder value and governance practices.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
On May 6, 2025, Clene Inc. received a notice from Nasdaq indicating that its market value of listed securities had fallen below the required $35 million for 30 consecutive business days, risking delisting if not rectified by November 3, 2025. Meanwhile, Clene is actively pursuing regulatory milestones, including a planned New Drug Application for CNM-Au8 in ALS, supported by recent data showing improved survival rates in ALS patients. The company is also preparing for discussions with the FDA regarding its neurofilament light chain biomarker data and has reported financial results showing a net loss decrease compared to the previous year.
On April 8, 2025, Clene announced the presentation of evidence demonstrating remyelination and neuronal repair with their CNM-Au8® treatment during the VISIONARY-MS LTE at the American Academy of Neurology Late-Breaking Science Session. This announcement highlights Clene’s ongoing efforts in advancing neurological treatments, potentially strengthening its position in the medical research industry and offering promising implications for stakeholders involved in neurological disorder therapies.